Stonemor Inc
Change company Symbol lookup
Select an option...
STON Stonemor Inc
$NQDM15LMCADN Nasdaq Developed Markets Telecommuni
BFZ BlackRock California Municipal Income Trust
CAR Avis Budget Group Inc
GIS General Mills Inc
VLN Valens Semiconductor Ltd
CIF MFS? Intermediate High Income Fund
LVOXW LiveVox Holdings Inc *W EXP 06/18/2026
SASR Sandy Spring Bancorp Inc
SWKH SWK Holdings Corp
Go

Consumer Discretionary : Diversified Consumer Services | Small Cap Value
Company profile

Stonemor Inc. is a provider of funeral and cemetery products and services in the death care industry. The Company's segments include Cemetery Operations and Funeral Home Operations. Cemetery Operations segment consists of sale of cemetery merchandise, which includes markers, bases, vaults, caskets and cremation niches and its cemetery services, which include opening and closing services, cremation services and fees for the installation of cemetery merchandise. Funeral Home Operations segment consists of sales of funeral home merchandise, which includes caskets and other funeral related items and service, which include services such as family consultation, the removal of and preparation of remains and the use of funeral home facilities for visitation and prayer services. Funeral Home Operations segment also include the sale of term and whole life insurance on an agency basis, in which it earn a commission from the sales of these insurance policies.

Closing Price
$2.50
Day's Change
-0.02 (-0.79%)
Bid
--
Ask
--
B/A Size
--
Day's High
2.58
Day's Low
2.45
Volume
(Heavy Day)
Volume:
145,271

10-day average volume:
100,664
145,271

Ocugen Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

4:52 pm ET September 17, 2021 (Globe Newswire) Print

Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced the Compensation Committee of the Board of Directors of Ocugen approved the grant of stock options to purchase an aggregate of 137,250 shares of its common stock and restricted stock units (RSUs) covering an aggregate of 23,000 shares of common stock to seven hired employees. The stock options and RSUs were granted as of September 16, 2021, as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options have a ten-year term and have an exercise price of $7.54 per share, which is the closing price of Ocugen's common stock on the grant date. The stock options and RSUs vest in equal annual installments over a three-year period starting on the one-year anniversary of the grant date, subject to the applicable new employee's continued service with Ocugen through the applicable vesting dates. The stock options and RSUs were granted outside of Ocugen's 2019 Equity Incentive Plan.

About Ocugen, Inc.

Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug -- "one to many," and our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. We are co-developing Bharat Biotech's COVAXIN(TM) vaccine candidate for COVID-19 in the U.S. and Canadian markets. For more information, please visit www.ocugen.com.

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from our current expectations, such as market and other conditions. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (the "SEC"), including the risk factors described in the section entitled "Risk Factors" in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events or otherwise, after the date of this press release.

Ocugen Contact:

Ken Inchausti

Head, Investor Relations & Communications

IR@Ocugen.com

https://ml.globenewswire.com/media/163cce64-f2fe-4170-bdba-c5b9826bb921/small/ocugen-logo-color-png.png

https://ml.globenewswire.com/media/163cce64-f2fe-4170-bdba-c5b9826bb921/small/ocugen-logo-color-png.png

comtex tracking

COMTEX_393529365/2010/2021-09-17T16:52:00

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.